Skip to main content

Table 1 Different trials

From: Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method

Trial

Column

Buffer

Mobile phase

Flow rate ml/min

Observation

1

Zorbax eclipse XDB-Phenyl (250×4.6mm, 5μm)

0.1% (V/V) formic acid

Buffer: ACN (50:50 v/v)

1.23

Peak tailing (1.3) and long retention time (9.52 min) of EVZ

2

Zorbax SB C8 (100×4.6mm, 5μm)

0.1% (V/V) formic acid

Buffer: ACN (35:65 v/v)

1.23

Resolution (1.5) was not good between LAM and TDF

3

Inertsil C8 (150×4.6mm, 5μm)

0.1% (V/V) formic acid

Buffer: ACN (35:65 v/v)

1.23

Resolution (1.6) was not good between LAM and TDF

4

Zorbax eclipse XDB-phenyl (250×4.6mm, 5μm)

0.1% (V/V) formic acid

Buffer: ACN (30:70 v/v)

1.23

Resolution was good, but retention time of EFV was long (8.056 min)

5

Phenyl XDB (250×4.6mm, 5μm)

0.1% (V/V) formic acid

Buffer: methanol (50:50 v/v)

1

Long retention time of EFV (7.201 min)

6

Phenyl XDB (250×4.6mm, 5μm)

0.1% (V/V) formic acid

Buffer: methanol (27:73 v/v)

1

Good resolution between LAM and TDF (9.13), TDF and EVZ (7.55), and less retention time (LAM-2.6 min, TDF-4.4 min, EVZ-5.9 min)

  1. XDB extra dense bonding, ACN acetonitrile, EFV efavirenz